Alpha Centric Advisors LLC Puma Biotechnology, Inc. Transaction History

Alpha Centric Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$2.12 - $5.08 $773,800 - $1.85 Million	-365,000 Reduced 87.95%	50,000 $212,000
Q3 2022 Nov 08, 2022	BUY	$2.27 - $3.84 $34,050 - $57,600	15,000 Added 3.75%	415,000 $984,000
Q4 2021 Feb 25, 2022	BUY	$2.85 - $6.58 $716,775 - $1.65 Million	251,500 Added 169.36%	400,000 $1.22 Million
Q3 2021 Mar 09, 2022	BUY	$6.63 - $9.39 $719,355 - $1.02 Million	108,500 Added 271.25%	148,500 $1.04 Million
Q2 2021 Mar 09, 2022	BUY	$8.98 - $11.6 $179,600 - $232,000	20,000 Added 100.0%	40,000 $367,000
Q1 2021 Mar 09, 2022	BUY	$9.38 - $13.63 $98,490 - $143,115	10,500 Added 110.53%	20,000 $194,000
Q4 2020 Mar 11, 2022	BUY	$7.78 - $12.13 $73,910 - $115,235	9,500 New	9,500 $97,000

102

29.1M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $132M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.